Caliway Pharma drug Cbl-514 shows statistically significant efficacy in Phase II trial
CALIWAY BIOPHARMACEUTICALS CO., LTD. announced on Sept. 21 that its new drug Cbl-514 demonstrated statistically significant efficacy in its Phase II clinical trial, meeting the primary efficacy endpoint.
, Ltd. said its new drug Cbl-514 Phase II clinical results met the primary efficacy endpoint and showed statistically significant efficacy. com; +852 3462 7745;))